Glax­o­SmithK­line sounds taps for a once-mighty R&D pro­gram

You could call it a fol­low-up case of an an­ti-in­flam­ma­to­ry flop for Glax­o­SmithK­line.

A year af­ter GSK shrugged off the fail­ure of losmapi­mod in pro­tect­ing high-risk heart fail­ure pa­tients, the phar­ma gi­ant says it will now shut­ter its R&D ef­fort for this drug on COPD. That news was buried in its Q3 re­lease Wednes­day morn­ing.

Two years ago GSK had mapped out am­bi­tious plans to put losmapi­mod through a huge de­vel­op­ment pro­gram, look­ing for da­ta to prove that the ther­a­py could pre­vent re­peat heart at­tacks. But that fell through last fall when the phar­ma gi­ant was forced to con­cede that the drug had proven to be a bust in the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.